No currently druggable targets were identified for ARHGAP27, ARL17A, DND1P1, LRRC37A2, LRRC37A4P, or RBM6. CRHR1 was identified in all databases as being a potential drug target with experimental medications available. Given the positive association between PTSD symptoms and imputed CRHR1 expression in multiple brain regions (with the exception of nucleus accumbens) seen in our dataset, a CRHR1 antagonist would be hypothesized to be potentially therapeutic. Another gene, PLEKHM1, which was significantly associated with imputed increased expression and colocalized in caudate and nucleus accumbens, was considered by CMap as highly likely to share biological effects with several classes of drugs, including dopamine receptor antagonists, acetylcholine receptor antagonists, and alpha-2 adrenergic receptor and angiotensin receptor antagonists, all of which would be predicted to reduce expression and be associated with a reduction in PTSD symptoms.
